Health Canada Approves ABECMA? (idecabtagene vicleucel), the First and Only Anti-BCMA CAR T cell Therapy for Relapsed and Refractory Multiple Myeloma
Through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities, BMS is advancing cell therapy research. Having established immunotherapy manufacturing facilities with cutting-edge technologies and highly trained manufacturing teams, BMS works to make cell therapy possible for Canadian patients in need. BMS' investment into the use of next-generation technology to optimize the manufacturing process and capacity will serve to decrease complexities and turnaround time, improve product control and reduce manufacturing costs. These efforts ultimately reduce the cost of these novel therapies to ensure patients can receive their treatment as quickly and as safely as possible. About Ide-cel
Ide-cel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy.34?The ide-cel CAR is comprised of a murine extracellular single-chain variable fragment (scFv) specific for recognizing BCMA followed by a human CD8a hinge and transmembrane domain fused to the T cell cytoplasmic signaling domains of CD137 (4-1BB) and CD3? chain, in tandem.35?Ide-cel recognizes and binds to BCMA on the surface of multiple myeloma cells leading to CAR-positive T cell proliferation, cytokine secretion, and subsequent cytolytic killing of BCMA-expressing cells.36 About Bristol Myers Squibb Canada
Bristol Myers Squibb Canada Co. is an indirect wholly-owned subsidiary of Bristol Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb global operations, visit?www.bms.com. Bristol Myers Squibb Canada Co. delivers innovative medicines for serious diseases to Canadian patients in the areas of cardiovascular health, oncology, and immunoscience. Bristol Myers Squibb Canada Co. employs close to 400 people across the country. For more information, please visit?www.bms.com/ca.
1?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
2?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
3?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
4?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
5?Wang DY, Johnson DB, Davis EJ. Toxicities associated with PD-1/PD-L1 blockade. Cancer J. 2018;24(1):36-40. |
||||||||||||
6?Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. |
||||||||||||
7?Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL.' Nat Rev Clin Oncol. 2018;15(4):218. |
||||||||||||
8?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
9?Canadian Cancer Society. Multiple Myeloma. Available at https://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/multiple-myeloma/?region=on. Accessed on February 5, 2021. |
||||||||||||
10?Canadian Cancer Society. Multiple myeloma statistics. Available at?https://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/statistics/?region=on. Accessed on February 5, 2021. |
||||||||||||
11?Myeloma Canada?| Statistics. Accessed March 17, 2021. |
||||||||||||
12?Kumar S. Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. Current Hematologic Malignancy Reports. 2011;6(2):104-112.?http://www.ncbi.nlm.nih.gov/pubmed/21394431. |
||||||||||||
13?Kumar S K, Lee J H, Lahuerta J J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157.?http://www.ncbi.nlm.nih.gov/pubmed/21799510. |
||||||||||||
14?Nijhof I, Donk N, Zweegman S, Lokhorst H. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs. 2018;78(1):19-37.?http://www.ncbi.nlm.nih.gov/pubmed/29188449. |
||||||||||||
15?Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology Am Soc Hematol Educ Program. 2017;2017(1):508-517.?http://www.ncbi.nlm.nih.gov/pubmed/29222299. |
||||||||||||
16?Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology Am Soc Hematol Educ Program. 2017;2017(1):508-517.?http://www.ncbi.nlm.nih.gov/pubmed/29222299. |
||||||||||||
17?Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37-44.?http://www.ncbi.nlm.nih.gov/pubmed/27216216. |
||||||||||||
18?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
19?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
20?Munshi N, Anderson L, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2021; 384(8): 705-716.?https://www.nejm.org/doi/full/10.1056/NEJMoa2024850 |
||||||||||||
21?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
22?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
23?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
24?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
25?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
26?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
27?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
28?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
29?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
30?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
31?ABECMA?TM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
32?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
33?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
34?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
35?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |
||||||||||||
36?ABECMATM?Product Monograph. Bristol Myers Squibb. May 27, 2021. |